First China Pharma, a rapidly growing pharmaceutical distribution company headquartered in Yunnan, China, announced the signing of an exclusive drug distribution agreement that clearly demonstrates its establishment as an industry leader. The agreement was signed on January 15 with Medisan Pharmaceutical of Harbin City to act as the exclusive distributor for the specialty drug Esmolol Hydrochloride, a short and rapid-acting beta class II anti-arrhythmic used for temporary control of heart rate and blood pressure. The product will be available to hospitals and clinics throughout China within the next 30 days and management estimates initial sales between US$650,000 and $1 million with the potential for significant growth as the company extends its market base throughout the nation. First China's chairman and CEO Mr Zhen Jiang Wang said, "The selection of First China by Medisan as its exclusive distributor of this life saving product is recognition that our business model delivers results. We are pleased to be aligned with Medisan and look forward to future opportunities to assist similar manufacturers in the timely and cost effective deployment of their products. These types of agreements are driving forces that clearly position our brand as an industry front runner in the effective distribution of pharmaceutical products." First China is buoyed by its successful and rapid penetration into the growing drug distribution marketplace in China and is committed to the further development of territorial expansion, joint partnerships and key acquisition strategies to drive the company towards achieving its stated goals in the months ahead.